Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
- Citation:
- N Engl J Med vol 353 (16) 1673-84
- Year:
- 2005
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10-CA-021115, U10-CA-12027, U10-CA-25224, U10-CA-31946, U10-CA-32102, U10-CA-37377, U10-CA-69651, U10-CA-69974
- Corr. Author:
- Edward H Romond
- Authors:
- Edward H Romond Edith A Perez John Bryant Vera J Suman Charles E Geyer Nancy E Davidson Elizabeth Tan-Chiu Silvana Martino Soonmyung Paik Peter A Kaufman Sandra M Swain Thomas M Pisansky Louis Fehrenbacher Leila A Kutteh Victor G Vogel Daniel W Visscher Greg Yothers Robert B Jenkins Ann M Brown Shaker R Dakhil Eleftherios P Mamounas Wilma L Lingle Pamela M Klein James N Ingle Norman Wolmark
- Networks:
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Female, Heart Diseases, Humans, Mastectomy, Middle Aged, Paclitaxel, Proportional Hazards Models, Receptor, ErbB-2, Recurrence, Survival Analysis, Trastuzumab